Premium
Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients
Author(s) -
OLSEN K. M.,
DEVLIN J. W.
Publication year - 2008
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2008.03728.x
Subject(s) - lansoprazole , medicine , enteral administration , pharmacodynamics , bioavailability , intensive care unit , pharmacokinetics , stress ulcer , intensive care , pharmacology , anesthesia , gastroenterology , parenteral nutrition , intensive care medicine , omeprazole
Aliment Pharmacol Ther 28 , 326–333 Summary Background While proton pump inhibitors are frequently administered in the intensive care unit, the pharmacodynamic response of acid suppression between the enteral and intravenous (IV) route is unknown. Aim To compare the pharmacodynamic response between enteral and IV lansoprazole in intensive care unit patients requiring stress ulcer prophylaxis therapy. Methods Adult mechanically ventilated patients were randomized to receive 72 h of daily enteral [lansoprazole oral disintegrating tablet (LODT) 30 mg mixed in 10 mL of water via a nasal gastric tube] or IV lansoprazole (30 mg over 30 min) therapy. Serial blood samples were collected after the first and third dose and analysed for pharmacokinetic parameters. Pharmacodynamic determination of intragastric pHmetry began prior to the first dose and continued for 72 h using a single channel pH micro‐electrode. Results Nineteen intensive care unit patients were randomized [LODT ( n = 10); IV‐L ( n = 9)]. LODT bioavailability was 76%. LODT maintained gastric pH > 4 longer than IV‐L at both 24 h (7.4 vs. 5.9 h; P = 0.039) and 72 h (10.4 and 8.9 h; P = 0.046) and resulted in a greater average pH over the first 24 h (3.67 vs. 2.89; P = 0.03). Conclusion Despite a lower bioavailability, enteral lansoprazole suppresses acid in intensive care unit patients to a greater extent than IV lansoprazole.